Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials… Read more
Bright Minds Biosciences Inc (DRUG) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.065x
Based on the latest financial reports, Bright Minds Biosciences Inc (DRUG) has a cash flow conversion efficiency ratio of -0.065x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.82 Million) by net assets ($89.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bright Minds Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Bright Minds Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bright Minds Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bright Minds Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enaex S.A
SN:ENAEX
|
0.106x |
|
Jinhui Liquor Co Ltd
SHG:603919
|
-0.011x |
|
Nuvoton Technology Corp
TW:4919
|
0.002x |
|
Happinet Corporation
PINK:HAPYF
|
N/A |
|
Rogers Sugar Inc
PINK:RSGUF
|
0.006x |
|
Shen Ma Industry Co Ltd
SHG:600810
|
0.029x |
|
Seegene Inc
KQ:096530
|
0.037x |
|
Guangdong Haomei New Material Co Lt
SHE:002988
|
0.017x |
Annual Cash Flow Conversion Efficiency for Bright Minds Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Bright Minds Biosciences Inc from 2019 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $82.04 Million | $-8.69 Million | -0.106x | +68.30% |
| 2024-09-30 | $5.54 Million | $-1.85 Million | -0.334x | +68.61% |
| 2023-09-30 | $6.60 Million | $-7.02 Million | -1.065x | +17.40% |
| 2022-09-30 | $10.54 Million | $-13.59 Million | -1.289x | -241.63% |
| 2021-09-30 | $19.40 Million | $-7.32 Million | -0.377x | +4.60% |
| 2020-09-30 | $729.29K | $-288.39K | -0.395x | -19.80% |
| 2019-09-30 | $127.26K | $-42.01K | -0.330x | -- |